Literature DB >> 17527072

Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.

Russell Vang1, Allen M Gown, Chengquan Zhao, Todd S Barry, Christina Isacson, Mary S Richardson, Brigitte M Ronnett.   

Abstract

Most primary ovarian mucinous tumors are of surface epithelial-stromal origin and exhibit diffuse expression of cytokeratin 7 (CK7) combined with variable expression of cytokeratin 20 (CK20); this immunoprofile distinguishes them from most lower gastrointestinal tract tumors secondarily involving the ovaries. The uncommon ovarian mucinous tumors of germ cell (teratomatous) origin have not been extensively evaluated to determine the utility of these markers and other markers of intestinal differentiation for distinguishing these tumors from metastatic gastrointestinal tract mucinous tumors. Immunohistochemical expression of CK7, CK20, CDX2, and villin was assessed in 44 ovarian mucinous tumors associated with a mature cystic teratoma. All cases lacked evidence of a nonovarian primary mucinous tumor. All mucinous tumors were unilateral; 6 cases had bilateral teratomas. All tumors displayed gastrointestinal-type mucinous differentiation, with epithelium that was commonly goblet cell-rich or hypermucinous; 21 were associated with pseudomyxoma ovarii and 3 of these had pseudomyxoma peritonei. Tumor architecture ranged from purely cystadenomatous (n=24), to proliferative (n=13), to carcinomatous (n=6); some tumors had admixtures of these patterns. One tumor had a goblet cell carcinoidlike pattern with pseudomyxoma ovarii. Three carcinomas had a signet ring cell component. Cystadenomatous tumors without pseudomyxoma ovarii (n=15) exhibited all possible CK7/CK20 coordinate expression profiles with nearly equal frequency. All proliferative tumors without pseudomyxoma ovarii (n=8) expressed CK7, most often in combination with CK20 expression. All cystadenomatous and proliferative tumors with pseudomyxoma ovarii (n=9 and n=5) were CK7-/CK20+. All carcinomatous tumors had pseudomyxoma ovarii; 3 were CK7-/CK20+, 2 were CK7+/CK20+, and 1 was CK7+/CK20-. The presence of pseudomyxoma ovarii was significantly associated with a CK7-/CK20+ profile (86% with pseudomyxoma ovarii vs. 13% without, P<0.0001), CDX2 positivity (79% vs. 0%, P<0.0001), and villin positivity (57% vs. 5%, P=0.0009). A subset of mucinous tumors associated with mature cystic teratomas exhibiting morphologic and immunohistochemical features of lower intestinal tract-type mucinous tumors may be teratomatous in origin. In practice, the more common diagnosis of secondary involvement by a lower intestinal tract mucinous tumor should be addressed in the pathology report and in subsequent clinical evaluation; interpretation as a true primary ovarian mucinous tumor of teratomatous origin can be considered as an alternative diagnosis when evaluation and follow-up fail to identify a nonovarian source of the mucinous tumor. Those tumors having CK7 expression with or without CK20 expression may be derived from upper gastrointestinal tract-type or sinonasal-type teratomatous elements but could be independent tumors of surface epithelial-stromal origin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17527072     DOI: 10.1097/PAS.0b013e31802efb45

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Authors:  Michiel Simons; Femke Simmer; Johan Bulten; Marjolijn J Ligtenberg; Harry Hollema; Shannon van Vliet; Richarda M de Voer; Eveline J Kamping; Dirk F van Essen; Bauke Ylstra; Lauren E Schwartz; Yihong Wang; Leon F Massuger; Iris D Nagtegaal; Robert J Kurman
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

2.  Mucinous Cystadenocarcinoma Co-Existing with Mature Cystic Teratoma : A Rare Case Report.

Authors:  Prachi Kukreja; Sunil Kumar Yeshvanth; Teerthanath Shrinivas; Tanu Agrawal; Jayaprakash K Shetty
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 3.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

Review 4.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

Review 5.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Mature embryoid teratoma in the wall of a mucinous cyst adenoma of ovary in multiparous female.

Authors:  Mohammed Naim; Nazima Haider; Vanesa T John; Seema Hakim
Journal:  BMJ Case Rep       Date:  2011-02-02

7.  Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin.

Authors:  Yihong Wang; Ren-chin Wu; Lauren Ende Shwartz; Lisa Haley; Ming-tse Lin; Ie-ming Shih; Robert J Kurman
Journal:  J Pathol       Date:  2015-07-23       Impact factor: 7.996

8.  Signet ring cell carcinoma of the appendix manifesting as colonic obstruction and ovarian tumors: report of a case.

Authors:  Jun Suzuki; Shinsuke Kazama; Joji Kitayama; Hiroshi Uozaki; Tetsuro Miyata; Hirokazu Nagawa
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

9.  High-level expression of divergent endodermal lineage markers in gonadal and extra-gonadal yolk sac tumors.

Authors:  Hadi Shojaei; Hong Hong; Raymond W Redline
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

Review 10.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.